FDA pursues shutdown recovery

Share this article:

Merck and Stallergenes are reclaiming their places in front of the FDA's advisory committees. The 16-day government shutdown scuttled the reviews of their allergy medications Grastek (Merck) and Oralair (Stallergenes), since they were not covered by the user fees that allowed the regulator to review and approve drugs while Congress froze government funding during the fight over healthcare reform.

The review committees are set for Dec. 12 (Merck) and Dec. 11 (Stallergenes).

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.